(Q42594989)

3 November 2017

title

Interferon treatment may trigger primary headaches in multiple sclerosis patients (English)

1 reference

3 November 2017

0 references

1 reference

5

G Bussone

1 reference

3 November 2017

L La Mantia

1

1 reference

3 November 2017

D D'Amico

2

1 reference

3 November 2017

A Rigamonti

3

1 reference

3 November 2017

N Mascoli

4

1 reference

3 November 2017

C Milanese

6

1 reference

3 November 2017

publication date

1 August 2006

1 reference

Multiple Sclerosis Journal

3 November 2017

published in

1 reference

3 November 2017

volume

12

1 reference

3 November 2017

issue

4

1 reference

3 November 2017

page(s)

476-480

1 reference

Side effect profile of interferon beta-1b in MS: results of an open label trial

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Multiple sclerosis: side effects of interferon beta therapy and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Interferons in relapsing remitting multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Neuromodulation by a cytokine: interferon-beta differentially augments neocortical neuronal activity and excitability

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Contemporary concepts of migraine pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Increased spontaneous release of tumor necrosis factor-alpha/cachectin in headache patients. A possible correlation with plasma endotoxin and hypothalamic-pituitary-adrenal axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Immunological aspects in migraine: increase of IL-10 plasma levels during attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Nitric oxide in primary headaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Evidence for increased nitric oxide production in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Interferon-beta-1-b (IFN-B) decreases induced nitric oxide (NO) production by a human astrocytoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Glatiramer acetate (Copaxone) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458506MS1298OA

10.1191/1352458506MS1298OA

21 January 2018

Identifiers

DOI

1 reference

3 November 2017

1 reference